Cargando...
Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?
The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed de...
Guardado en:
| Publicado en: | Hemasphere |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Health
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6919470/ https://ncbi.nlm.nih.gov/pubmed/31942542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000287 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|